Patent 7951784 was granted and assigned to University of Massachusetts on May, 2011 by the United States Patent and Trademark Office.
The invention features chemically modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA. The features siRNA are effective therapeutics, particularly for targeting SOD1.